HCL and UNLEASH Partner to Develop Solutions for Aquatic Ecosystem Conservation
20.5.2022 18:59:00 EEST | Business Wire | Press release
HCL Group and UNLEASH, a global innovation program for the UN Sustainable Development Goals (SDGs), announced a year-long collaboration to mobilize youth and develop innovative solutions to promote aquatic ecosystem conservation. These solutions will aim to tackle challenges from Source (mountains & glaciers) to Sink (oceans and seas) and their links to terrestrial ecosystems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220520005178/en/
Nature and ocean conservation play a critical role in our survival. Terrestrial and aquatic ecosystems provide us with food, water, oxygen, energy, and medicines. They regulate our climate, provide pollination to crops, and reduce the impact of natural hazards.
Despite the vital importance of our planet’s ecosystems, we are experiencing a human-caused deterioration of our natural habitats: human activity has altered almost 75% of the Earth’s terrestrial surface, squeezing wildlife and nature into an ever-smaller corner.1 Furthermore, ocean heat is at record levels and every year up to 12 million metric tonnes of plastic enter the ocean, damaging ecosystems around the world. Without maintaining healthy and biodiverse terrestrial and aquatic ecosystems, the progress on the remaining United Nations’ SDGs is at critical risk.
To tackle such challenges, UNLEASH and HCL will collaborate to establish a year of youth-led action. Specifically, the partnership will allow youth to develop solutions encompassing SDG 14 (Life below water) and SDG 15 (Life on land), and explore synergies with other SDGs as well. During the process, they will be guided by industry experts and receive hands-on support to ensure that solutions are relatable to the context and feasible in practice.
HCL Group with its large presence in business through HCL Technologies, HCL Infosystems and HCL Healthcare; and its social development organizations including the philanthropic Shiv Nadar Foundation and The Habitats Trust, and its CSR arm – HCL Foundation, has been tackling real on-ground issues related to the SDGs. The Group with its breadth of experience across different sectors and its holistic and powerful sustainability charter is the perfect partner for UNLEASH to successfully push its SDGs innovation efforts.
“Innovation, entrepreneurship, humanity and a people-centric culture are part of HCL’s core, and it is important to us that our progress is reflected in the development of a better world. Our various entities have already been driving important projects to help create a positive impact for the people and the planet. HCL’s collaboration with UNLEASH in bringing innovation to the SDGs, and specifically to the preservation of nature and ocean conservation is an essential step in our overall sustainability efforts”, said Roshni Nadar Malhotra, CEO of HCL, Chairperson of HCL Technologies, Trustee of Shiv Nadar Foundation & Founder of The Habitats Trust.
With HCL’s continuous support on the thematic track From Source to Sink, UNLEASH Talents will have the opportunity to work on localized challenges through joining an UNLEASH Hack at the Shiv Nadar University, Delhi NCR (part of the HCL Group). Earlier this year, UNLEASH Talents participated in three other UNLEASH Hacks related to this theme, exploring challenges of water ecosystems from the Mediterranean, the Danube, Haiti and Hawaii and defining solutions that can drive positive local impact on those regions. The partnership will help scale an existing early-stage solution in the biodiversity space through enrolment in an incubation program, UNLEASH Plus. Thematic insight sessions will be organized throughout 2022, providing inspiration and key learnings on the essence of the theme. These year-long efforts will culminate in the Global Innovation Lab in India that will witness a gathering of 1000+ talented youth for a week long innovation process and help them develop solutions for Indian and global challenges within aquatic and terrestrial ecosystem conservation. The best solutions from the Lab will take home grant prizes to kick-start implementation of the developed solutions. Through the course of this partnership, HCL will enable access to its celebrated business leaders, technical experts, and faculty and academicians of global repute to serve as facilitators, mentors and experts that will help participants across the various programs to develop innovative solutions.
The partnership enables UNLEASH to dive deep into SDG14 and SDG15, and truly establish a community of changemakers, working with nature challenges.
“HCL’s journey in innovation and development is an inspiration for the entire UNLEASH Community. We are very grateful for their partnership on an important matter such as the aquatic conservation of our planet and finding solutions for its preservation through our different programs during the course of this year”, said UNLEASH Chairman Flemming Besenbacher.
About HCL Group
Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978 well before its global peers. Today, the HCL Group has business presence across sectors including technology and healthcare and comprises three group companies –HCL Technologies, HCL Infosystems and HCL Healthcare. The Group generates annual revenues of over US$11.5 billion with more than 209,000 employees operating across 52 countries.
The Group also includes one of India’s most prolific philanthropic foundations – the Shiv Nadar Foundation. Established in 1994, the Foundation is committed to the creation of a more equitable, merit-based society by empowering individuals through transformational education. Over the last 27 years, it has invested over US$1billion in seven landmark institutions and initiatives across education and art. The Habitats Trust, also a philanthropic Foundation within the HCL Group, specifically works towards protecting natural habitats and their indigenous species of flora and fauna. Established in 2018, the young foundation is undertaking important initiatives that will help secure a positive future for wild species and their habitats.
HCL Foundation, the Corporate Social Responsibility arm of HCL, has instituted flagship programs and initiatives to contribute towards SDGs. Its work is helping bring about lasting positive impact on the people and planet, through long-term sustainable programs, and ensure equitable access, opportunities, and holistic development for all.
For further information, visit www.hcl.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220520005178/en/
Contact information
For any queries or information, please contact:
Sadaf Khan | Sadaf-k@hcl.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
